Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.70 |
| ▸ | MMP9 | P14780 | 13/20 | 0.70 |
| ▸ | MMP1 | P03956 | 6/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.70 |
| ▸ | MMP2 | P08253 | 15/20 | 0.59 |
| ▸ | MMP8 | P22894 | 15/20 | 0.59 |
| ▸ | MMP3 | P08254 | 3/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206523 | 0.89 | MMP13 (0.53) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL6207339 | 0.85 | MMP13 (0.49) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL6205603 | 0.83 | MMP13 (0.49) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL8321743 | 0.82 | MMP13 (0.57) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL8316976 | 0.81 | MMP8 (0.53) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL6697733 | 0.80 | MMP8 (0.54) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5919322 | 0.80 | MMP13 (0.94) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL6207341 | 0.77 | MMP13 (0.40) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL5908643 | 0.75 | MMP13 (0.77) | MMP13MMP9MMP1ADAM17MMP2 | |
| SCHEMBL8322254 | 0.72 | MMP13 (0.76) | MMP13MMP9MMP1ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565459-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | MMP13 2/4885MMP9 7/4885MMP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.